TEVA - テバ・ファ―マス―ティカル・インダストリ―ズ ()


   Teva Launches Two Digital Inhalers For Asthma Patients  2020/09/22 11:31:17 Smarter Analyst
Teva Pharmaceutical Industries launched two new digital inhalers AirDuo Digihaler and ArmonAir Digihaler in the US for patients with Asthma. With these two … The post Teva Launches Two Digital Inhalers For Asthma Patients appeared first on Smarter Analyst .
   Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020: Comprehensive Listing of 2,300+ Clinical Stage Partnering Deals  2020/09/18 17:30:00 Benzinga
DUBLIN , Sept. 18, 2020 /PRNewswire/ -- The "Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020" report has been added to's offering. The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals and provides details of the latest clinical agreements announced in the healthcare sector. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of over 2,300 clinical stage partnering deals announced since 2014 including financial terms where available including numerous links to online deal records of actual clinical partnering deals as disclosed by the deal parties.
   Telehealth company Amwell is going public after raising $742 million in its IPO. Here are the investors and execs who stand to make the most.  2020/09/17 12:44:20 Business Insider
Summary List Placement American Well raised $742 million ahead of its public market debut, pricing at $18 a share late Wednesday. The stock is set to start trading Thursday morning. As the company goes public, executives including Ido and Roy Schoenberg, the company's founders and CEOs, and investors including Teva Pharmaceuticals stand to make hundreds of millions. The IPO comes on the heels of a huge year for digital health as the coronavirus pandemic fueled Amwell and similar companies to new heights. It's only the second telehealth company to go public, following rival Teladoc's public debut in 2015. SVB Leerink's Stephanie Davis, a healthcare analyst, said the IPO is leading to "the match we've all been waiting for" in an email to investors. But she also said the Teladoc-Amwell rivalry isn't a zero-sum game. "Rather than viewing growth in Teladoc and American Well as a zero sum game, we believe the virtual care market has more than enough greenfield opportunity to sustain multiple winners in the near to mid-term," Davis wrote.
   First Long-Term Data on the use of AJOVY® (fremanezumab-vfrm) Injection in Patients with Migraine Published in Neurology  2020/09/15 12:00:00 Business Wire
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that results from the 52-week, multicenter, randomized, double-blind, parallel group study evaluating monthly or quarterly AJOVY® (fremanezumab-vfrm) injection in adults with chronic migraine (CM) or episodic migraine (EM), were published online ahead of print in Neurology. “Migraine can be a difficult disease to treat, and is often debilitating for those who suffer from it,” said Denisa Hurtuk
   Teva to Present New Data at The MDS Virtual Congress 2020 and Psych Congress 2020 Virtual Experience Evaluating Long-Term Treatment with AUSTEDO® (deutetrabenazine) Tablets  2020/09/14 12:00:00 Business Wire
JERUSALEM & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Neuroscience, Inc., an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will present new study data on AUSTEDO at the International Parkinson and Movement Disorder Society annual congress (MDS Virtual Congress 2020) and Psych Congress 2020 Virtual Experience evaluating the long-term efficacy and safety of AUSTEDO in patients with tardive dyskinesia (TD), and the safety and tolerability of AUSTEDO during periods of titrati